Acadia Rewrites Its Alzheimer's Psychosis Phase 3 Plan After Phase 2 Narrowly Missed, With A p-Value Of 0.0603
Management will change the statistics, raters and sites for remlifanserin's late-stage trial but keep patient entry criteria unchanged.
Acadia Pharmaceuticals, which develops drugs for neurological and rare diseases, will rework the statistical plan, rater use and site selection for the Phase 3 trial of its Alzheimer's psychosis drug remlifanserin, management said on its third-quarter earnings call Wednesday. The Phase 2 portion missed its main goal with a p-value of 0.0603, just short of statistical significance.
A near-miss, and what changes
Dr. Sanjit Pathak, Acadia's senior vice president and head of clinical development, said the 60 mg dose showed "a clear and consistent signal of activity." Effect sizes were 0.26 on the primary endpoint and 0.37 on a key secondary measure, which reached nominal significance with a p-value of 0.0077, he said.
Acadia will drop the 30 mg arm, which showed minimal efficacy, refine site selection using Phase 2 performance, expand central raters where local rating was difficult, and modify the statistical plan. Pathak said Acadia is making "no change in inclusion-exclusion criteria."
Pathak also said patients with higher baseline severity showed greater treatment effects, and that severity will be built into the statistical modifications. Safety was similar to placebo, with no deaths in remlifanserin arms, he said.
Analysts press for numbers
An RBC Capital Markets analyst asked what effect size the optimized design might have produced. CEO Catherine Owen Adams said the company would not give specifics, and Pathak said Acadia wants to keep parts of its statistical methodology confidential to protect the trial's integrity.
Pathak said the primary endpoint remains SAPS-H&D. He placed a meeting with the FDA in the second quarter of 2027, while Adams referred to FDA discussions in the first quarter, so the timing was stated two ways on the call.
The $4 billion bet and the business behind it
Adams put the combined peak sales opportunity for remlifanserin in Alzheimer's and Lewy body dementia psychosis at approximately $4 billion. Acadia expects Phase 2 results in Lewy body dementia psychosis in the fourth quarter of 2027, and that study will keep testing both 30 mg and 60 mg doses.
The pipeline sits atop two marketed drugs, NUPLAZID and DAYBUE, which together had $1,071.5 million in net sales in 2025. For the third quarter, Adams reported total revenues of $342 million, with DAYBUE at $140 million and NUPLAZID at $202 million. Cash ended the quarter at $976 million, and the company's market value was about $3.5 billion.
Acadia will present more RADIANT data at the CTAD conference later this month, which the original report places in Boston on Nov. 17.
Sources
- Acadia: Q3 Earnings Snapshot — Associated Press
- Acadia Pharma GAAP EPS of $0.31 beats by $0.12, revenue of $342M beats by $9.45M | Seeking Alpha — seekingalpha.com
- Acadia: Q3 Earnings Snapshot | wfaa.com — Associated Press
- Acadia: Q3 Earnings Snapshot | king5.com — Associated Press
- Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results — businesswire.com